This study shows that liquid biopsy—blood-based tumor DNA testing—reveals widespread treatment-resistance mutations across 12,827 patients with metastatic breast cancer.
This study identifies which mutations most strongly drive hepatocellular carcinoma—liver cancer—in Chinese patients by measuring each mutation's selective advantage.